FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:C4B-DLK1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: C4B-DLK1
FusionPDB ID: 11766
FusionGDB2.0 ID: 11766
HgeneTgene
Gene symbol

C4B

DLK1

Gene ID

721

8788

Gene namecomplement C4B (Chido blood group)delta like non-canonical Notch ligand 1
SynonymsC4B1|C4B12|C4B2|C4B3|C4B5|C4BD|C4B_2|C4F|CH|CO4|CPAMD3DLK|DLK-1|Delta1|FA1|PREF1|Pref-1|ZOG|pG2
Cytomap

6p21.33

14q32.2

Type of geneprotein-codingprotein-coding
Descriptioncomplement C4-BC3 and PZP-like alpha-2-macroglobulin domain-containing protein 3Chido form of C4basic complement C4complement C4B1acomplement component 4B (Chido blood group)protein delta homolog 1delta-like 1 homologfetal antigen 1preadipocyte factor 1secredeltin
Modification date2020031320200329
UniProtAcc

P04003

Main function of 5'-partner protein: FUNCTION: Controls the classical pathway of complement activation. It binds as a cofactor to C3b/C4b inactivator (C3bINA), which then hydrolyzes the complement fragment C4b. It also accelerates the degradation of the C4bC2a complex (C3 convertase) by dissociating the complement fragment C2a. Alpha chain binds C4b. It interacts also with anticoagulant protein S and with serum amyloid P component.

P80370

Main function of 5'-partner protein: FUNCTION: May have a role in neuroendocrine differentiation.
Ensembl transtripts involved in fusion geneENST idsENST00000435363, ENST00000375177, 
ENST00000411583, ENST00000425700, 
ENST00000445788, ENST00000449788, 
ENST00000485543, ENST00000487226, 
ENST00000488817, ENST00000494210, 
ENST00000546399, ENST00000548301, 
ENST00000548530, ENST00000550398, 
ENST00000556051, ENST00000331224, 
ENST00000341267, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score9 X 7 X 6=37811 X 12 X 3=396
# samples 810
** MAII scorelog2(8/378*10)=-2.24031432933371
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(10/396*10)=-1.98550043030488
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: C4B [Title/Abstract] AND DLK1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: C4B [Title/Abstract] AND DLK1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)C4B(31999910)-DLK1(101200985), # samples:1
Anticipated loss of major functional domain due to fusion event.C4B-DLK1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
C4B-DLK1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
C4B-DLK1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
C4B-DLK1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneC4B

GO:0032490

detection of molecule of bacterial origin

22333221

TgeneDLK1

GO:0045746

negative regulation of Notch signaling pathway

25093684



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr6:31999910/chr14:101200985)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across C4B (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across DLK1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000435363C4Bchr631999910+ENST00000341267DLK1chr14101200985+514745936948021577
ENST00000435363C4Bchr631999910+ENST00000331224DLK1chr14101200985+507345936948411590

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000435363ENST00000341267C4Bchr631999910+DLK1chr14101200985+0.0022401850.9977598
ENST00000435363ENST00000331224C4Bchr631999910+DLK1chr14101200985+0.0019891230.99801093

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for C4B-DLK1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
C4Bchr631999910DLK1chr1410120098545931508LSGFHALRADLEKARPSASPSWACSP
C4Bchr631999910DLK1chr1410120098545931508LSGFHALRADLEKGQAICFTILGVLT

Top

Potential FusionNeoAntigen Information of C4B-DLK1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
C4B-DLK1_31999910_101200985.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
C4B-DLK1chr631999910chr141012009854593HLA-B40:02ADLEKGQAI0.98880.5232817
C4B-DLK1chr631999910chr141012009854593HLA-B44:03LEKGQAICF0.98060.72991019
C4B-DLK1chr631999910chr141012009854593HLA-B18:01LEKGQAICF0.97720.52461019
C4B-DLK1chr631999910chr141012009854593HLA-B57:01KARPSASPSW0.99980.95471222
C4B-DLK1chr631999910chr141012009854593HLA-B58:02KARPSASPSW0.99940.93591222
C4B-DLK1chr631999910chr141012009854593HLA-B58:01KARPSASPSW0.9980.9181222
C4B-DLK1chr631999910chr141012009854593HLA-B57:03KARPSASPSW0.99790.98031222
C4B-DLK1chr631999910chr141012009854593HLA-B15:16KARPSASPSW0.99680.73271222
C4B-DLK1chr631999910chr141012009854593HLA-B15:17KARPSASPSW0.99540.82111222
C4B-DLK1chr631999910chr141012009854593HLA-A32:13KARPSASPSW0.85080.94871222
C4B-DLK1chr631999910chr141012009854593HLA-B18:01DLEKGQAICF0.52190.7046919
C4B-DLK1chr631999910chr141012009854593HLA-B57:01EKARPSASPSW0.99970.77141122
C4B-DLK1chr631999910chr141012009854593HLA-B39:08ADLEKGQAI0.60890.955817
C4B-DLK1chr631999910chr141012009854593HLA-C05:09RADLEKGQAI0.99990.9583717
C4B-DLK1chr631999910chr141012009854593HLA-C08:15RADLEKGQAI0.99980.9803717
C4B-DLK1chr631999910chr141012009854593HLA-A02:03ALRADLEKA0.99510.6264514
C4B-DLK1chr631999910chr141012009854593HLA-B18:04LEKGQAICF0.98550.5551019
C4B-DLK1chr631999910chr141012009854593HLA-B40:40ADLEKGQAI0.98180.5782817
C4B-DLK1chr631999910chr141012009854593HLA-A30:01KARPSASPS0.98120.94331221
C4B-DLK1chr631999910chr141012009854593HLA-B44:13LEKGQAICF0.98060.72991019
C4B-DLK1chr631999910chr141012009854593HLA-B44:26LEKGQAICF0.98060.72991019
C4B-DLK1chr631999910chr141012009854593HLA-B44:07LEKGQAICF0.98060.72991019
C4B-DLK1chr631999910chr141012009854593HLA-B18:05LEKGQAICF0.97720.52461019
C4B-DLK1chr631999910chr141012009854593HLA-B18:06LEKGQAICF0.97440.5281019
C4B-DLK1chr631999910chr141012009854593HLA-B18:03LEKGQAICF0.96410.50941019
C4B-DLK1chr631999910chr141012009854593HLA-B18:11LEKGQAICF0.81730.56581019
C4B-DLK1chr631999910chr141012009854593HLA-B15:53LEKGQAICF0.78940.51821019
C4B-DLK1chr631999910chr141012009854593HLA-B41:03ADLEKGQAI0.76640.9079817
C4B-DLK1chr631999910chr141012009854593HLA-B48:02LEKGQAICF0.16480.56861019
C4B-DLK1chr631999910chr141012009854593HLA-C05:01RADLEKGQAI0.99990.9583717
C4B-DLK1chr631999910chr141012009854593HLA-C08:02RADLEKGQAI0.99980.9803717
C4B-DLK1chr631999910chr141012009854593HLA-B57:10KARPSASPSW0.99980.95471222
C4B-DLK1chr631999910chr141012009854593HLA-B57:04KARPSASPSW0.99890.82521222
C4B-DLK1chr631999910chr141012009854593HLA-B58:06KARPSASPSW0.99880.93891222
C4B-DLK1chr631999910chr141012009854593HLA-B15:24KARPSASPSW0.99610.85541222
C4B-DLK1chr631999910chr141012009854593HLA-A32:01KARPSASPSW0.98550.95891222
C4B-DLK1chr631999910chr141012009854593HLA-B15:13KARPSASPSW0.98360.76061222
C4B-DLK1chr631999910chr141012009854593HLA-B57:02KARPSASPSW0.97890.95131222
C4B-DLK1chr631999910chr141012009854593HLA-B07:13RADLEKGQAI0.83970.8953717
C4B-DLK1chr631999910chr141012009854593HLA-B18:03DLEKGQAICF0.52420.6798919
C4B-DLK1chr631999910chr141012009854593HLA-B18:05DLEKGQAICF0.52190.7046919
C4B-DLK1chr631999910chr141012009854593HLA-B57:10EKARPSASPSW0.99970.77141122

Top

Potential FusionNeoAntigen Information of C4B-DLK1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
C4B-DLK1_31999910_101200985.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
C4B-DLK1chr631999910chr141012009854593DRB1-0301FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0301GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0307FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0307GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0313FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0313GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0318FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0318GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0320FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0320GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0322FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0322GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0328FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0328GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0330FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0330GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0332FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0332GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0334FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0334GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0336FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0336GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0342FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0342GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0344FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0344GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0346FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0346GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0348FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0348GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0350FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0350GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0352FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0352GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0354FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-0354GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-0405LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0405LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0409LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0409LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0417LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0417LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0424LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0424LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0429LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0429LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0430LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0430LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0445LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0445LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0447LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0447LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0448LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0448LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0457LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0457LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0462LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0462LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0477LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0477LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0480LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0480SGFHALRADLEKGQA116
C4B-DLK1chr631999910chr141012009854593DRB1-0480LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0480SGFHALRADLEKARP116
C4B-DLK1chr631999910chr141012009854593DRB1-0482LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0482LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0483LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0483LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0484LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0484LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0486LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0486LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0487LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0487SGFHALRADLEKGQA116
C4B-DLK1chr631999910chr141012009854593DRB1-0487LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0487SGFHALRADLEKARP116
C4B-DLK1chr631999910chr141012009854593DRB1-0489LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0489LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0832LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-0832SGFHALRADLEKGQA116
C4B-DLK1chr631999910chr141012009854593DRB1-0832LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-0832SGFHALRADLEKARP116
C4B-DLK1chr631999910chr141012009854593DRB1-1001LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-1001SGFHALRADLEKGQA116
C4B-DLK1chr631999910chr141012009854593DRB1-1001LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-1001SGFHALRADLEKARP116
C4B-DLK1chr631999910chr141012009854593DRB1-1003LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-1003SGFHALRADLEKGQA116
C4B-DLK1chr631999910chr141012009854593DRB1-1003LSGFHALRADLEKAR015
C4B-DLK1chr631999910chr141012009854593DRB1-1003SGFHALRADLEKARP116
C4B-DLK1chr631999910chr141012009854593DRB1-1107FHALRADLEKARPSA318
C4B-DLK1chr631999910chr141012009854593DRB1-1107GFHALRADLEKARPS217
C4B-DLK1chr631999910chr141012009854593DRB1-1216LSGFHALRADLEKGQ015
C4B-DLK1chr631999910chr141012009854593DRB1-1216LSGFHALRADLEKAR015

Top

Fusion breakpoint peptide structures of C4B-DLK1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
5503LRADLEKARPSASPC4BDLK1chr631999910chr141012009854593
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
5504LRADLEKGQAICFTC4BDLK1chr631999910chr141012009854593

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of C4B-DLK1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN5503LRADLEKARPSASP-7.88372-7.99712
HLA-B14:023BVN5503LRADLEKARPSASP-5.34165-6.37695
HLA-B52:013W395503LRADLEKARPSASP-6.76573-6.87913
HLA-B52:013W395503LRADLEKARPSASP-5.28832-6.32362
HLA-A24:025HGA5503LRADLEKARPSASP-7.78551-7.89891
HLA-A24:025HGA5503LRADLEKARPSASP-5.13058-6.16588
HLA-B44:053DX85503LRADLEKARPSASP-6.02716-6.14056
HLA-B44:053DX85503LRADLEKARPSASP-3.54334-4.57864
HLA-A02:016TDR5503LRADLEKARPSASP-4.9342-5.0476
HLA-A02:016TDR5503LRADLEKARPSASP-1.37769-2.41299
HLA-B14:023BVN5504LRADLEKGQAICFT-7.15543-7.26883
HLA-B14:023BVN5504LRADLEKGQAICFT-4.77435-5.80965
HLA-B52:013W395504LRADLEKGQAICFT-6.80875-6.92215
HLA-B52:013W395504LRADLEKGQAICFT-4.20386-5.23916
HLA-A11:014UQ25504LRADLEKGQAICFT-7.5194-8.5547
HLA-A11:014UQ25504LRADLEKGQAICFT-6.9601-7.0735
HLA-A24:025HGA5504LRADLEKGQAICFT-7.52403-7.63743
HLA-A24:025HGA5504LRADLEKGQAICFT-5.82433-6.85963
HLA-B27:056PYJ5504LRADLEKGQAICFT-3.28285-4.31815
HLA-B44:053DX85504LRADLEKGQAICFT-5.91172-6.94702
HLA-B44:053DX85504LRADLEKGQAICFT-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of C4B-DLK1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
C4B-DLK1chr631999910chr141012009851019LEKGQAICFCTGGAGAAGGGCCAGGCCATCTGCTTC
C4B-DLK1chr631999910chr141012009851122EKARPSASPSWGAGAAGGCCAGGCCATCTGCTTCACCATCCTGG
C4B-DLK1chr631999910chr141012009851221KARPSASPSAAGGCCAGGCCATCTGCTTCACCATCC
C4B-DLK1chr631999910chr141012009851222KARPSASPSWAAGGCCAGGCCATCTGCTTCACCATCCTGG
C4B-DLK1chr631999910chr14101200985514ALRADLEKAGCCCTGCGTGCTGACCTGGAGAAGGCC
C4B-DLK1chr631999910chr14101200985717RADLEKGQAICGTGCTGACCTGGAGAAGGGCCAGGCCATC
C4B-DLK1chr631999910chr14101200985817ADLEKGQAIGCTGACCTGGAGAAGGGCCAGGCCATC
C4B-DLK1chr631999910chr14101200985919DLEKGQAICFGACCTGGAGAAGGGCCAGGCCATCTGCTTC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
C4B-DLK1chr631999910chr14101200985015LSGFHALRADLEKARCTGAGTGGATTCCACGCCCTGCGTGCTGACCTGGAGAAGGCCAGG
C4B-DLK1chr631999910chr14101200985015LSGFHALRADLEKGQCTGAGTGGATTCCACGCCCTGCGTGCTGACCTGGAGAAGGGCCAG
C4B-DLK1chr631999910chr14101200985116SGFHALRADLEKARPAGTGGATTCCACGCCCTGCGTGCTGACCTGGAGAAGGCCAGGCCA
C4B-DLK1chr631999910chr14101200985116SGFHALRADLEKGQAAGTGGATTCCACGCCCTGCGTGCTGACCTGGAGAAGGGCCAGGCC
C4B-DLK1chr631999910chr14101200985217GFHALRADLEKARPSGGATTCCACGCCCTGCGTGCTGACCTGGAGAAGGCCAGGCCATCT
C4B-DLK1chr631999910chr14101200985318FHALRADLEKARPSATTCCACGCCCTGCGTGCTGACCTGGAGAAGGCCAGGCCATCTGCT

Top

Information of the samples that have these potential fusion neoantigens of C4B-DLK1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
ACCC4B-DLK1chr631999910ENST00000435363chr14101200985ENST00000331224TCGA-OR-A5JT-01A
ACCC4B-DLK1chr631999910ENST00000435363chr14101200985ENST00000341267TCGA-OR-A5JT-01A

Top

Potential target of CAR-T therapy development for C4B-DLK1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneDLK1chr6:31999910chr14:101200985ENST0000033122446304_3270311.0TransmembraneHelical
TgeneDLK1chr6:31999910chr14:101200985ENST0000034126705304_3270384.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to C4B-DLK1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to C4B-DLK1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource